Bristol-Myers Squibb cuts 2026 adjusted EPS forecast to $6.35-$6.55

Bitget2026/10/29 11:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bristol-Myers Squibb raised 2026 revenue guidance to $49.75 billion-$50.25 billion from $49 billion-$50 billion.
Adjusted diluted earnings guidance fell to $6.35-$6.55 per share from $6.75-$7, incorporating a $0.58 third-quarter acquisition-related research and licensing impact.
The higher revenue outlook reflects year-to-date strength, including continued Growth Portfolio momentum; third-quarter portfolio revenue rose 12% to $7.7 billion.
Legacy Portfolio revenue is expected to decline 3%-5%, with worldwide Eliquis revenue forecast to grow 20%-25%.
Gross margin guidance remained approximately 69%-70%; operating expenses are still projected at approximately $16.5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bristol-Myers Squibb cuts 2026 adjusted EPS forecast to $6.35-$6.55

You may also like

Crypto prices